ASP Isotopes (NASDAQ:ASPI) Price Target Increased to $5.50 by Analysts at HC Wainwright

ASP Isotopes (NASDAQ:ASPI) had its price objective boosted by HC Wainwright from $5.25 to $5.50 in a report released on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for ASP Isotopes’ FY2025 earnings at ($0.07) EPS.

ASP Isotopes Trading Down 3.8 %

ASPI opened at $3.04 on Wednesday. The business has a fifty day moving average price of $3.67 and a 200 day moving average price of $2.38. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.85 and a quick ratio of 1.85. ASP Isotopes has a 12 month low of $0.28 and a 12 month high of $4.97. The stock has a market capitalization of $148.72 million, a price-to-earnings ratio of -6.20 and a beta of 5.03.

Insider Buying and Selling at ASP Isotopes

In other news, Director Robert John Andrew Ryan bought 15,596 shares of ASP Isotopes stock in a transaction dated Monday, January 29th. The stock was acquired at an average cost of $2.35 per share, with a total value of $36,650.60. Following the acquisition, the director now owns 537,055 shares of the company’s stock, valued at $1,262,079.25. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 26.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of ASPI. Millennium Management LLC acquired a new stake in ASP Isotopes in the fourth quarter valued at $49,000. Armistice Capital LLC purchased a new position in shares of ASP Isotopes in the 1st quarter valued at about $2,702,000. Renaissance Technologies LLC acquired a new stake in shares of ASP Isotopes in the second quarter valued at about $272,000. HTLF Bank purchased a new stake in ASP Isotopes during the fourth quarter worth about $141,000. Finally, Rathbones Group PLC acquired a new position in ASP Isotopes during the fourth quarter worth about $272,000. Institutional investors and hedge funds own 16.80% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.